Estrella Immunopharma (ESLA) Total Liabilities (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Total Liabilities of $8.9 million for Q1 2026, up 108.82% year-over-year from $4.3 million in Q1 2025, and down 34.08% quarter-over-quarter from $13.5 million in Q4 2025.
Estrella Immunopharma (ESLA) Total Liabilities (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Total Liabilities for 6 consecutive years, with $8.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 108.82% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 108.82% YoY), while the FY2025 annual figure was $13.5 million, up 351.88% from the prior year.
- Total Liabilities slipped to $8.9 million in Q1 2026 per ESLA's latest filing, from $13.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $17.3 million in Q3 2023 and bottomed at $138491.0 in Q1 2024.
- Historically, Total Liabilities has averaged $5.5 million across 5 years, with a median of $3.0 million in 2024.
- Annual changes were most pronounced in 2024 — Total Liabilities tumbled 98.15% — and 2025, when it surged 4922.22%.
- Estrella Immunopharma's Total Liabilities stood at $2.7 million in 2022, then plunged by 84.97% to $398733.0 in 2023, then jumped by 651.64% to $3.0 million in 2024, then surged by 351.88% to $13.5 million in 2025, then slumped by 34.08% to $8.9 million in 2026.
- Business Quant data shows ESLA's Total Liabilities at $8.9 million in Q1 2026, $13.5 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | 9.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.26 Mn |
| Mar 31, 2026 | 8.93 Mn |
| Dec 31, 2025 | 13.54 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 9.08 Mn |
| Mar 31, 2025 | 4.28 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 180,701.00 |
| Mar 31, 2024 | 138,491.00 |
| Dec 31, 2023 | 398,733.00 |
| Sep 30, 2023 | 17.28 Mn |
| Jun 30, 2023 | 9.77 Mn |
| Mar 31, 2023 | 2.77 Mn |
| Dec 31, 2022 | 2.65 Mn |
| Sep 30, 2022 | 2.29 Mn |
| Jun 30, 2022 | 1.71 Mn |
| Mar 31, 2022 | 1.58 Mn |
| Dec 31, 2021 | 1.62 Mn |
| Sep 30, 2021 | 1.65 Mn |